Q1 2025 Perrigo Co PLC Earnings Call
Operator: Ladies and gentlemen, this is the operator. Today's conference is scheduled to begin momentarily until that your lines will remain on music hold. Thank you for your patience.
Speaker Change: Good morning, ladies and gentlemen, and welcome to the Perrigo Q1 2025 Financial Results
At this time, all lines are in listen only mode [inaudible]
Speaker Change: Following the presentation, we will conduct a question and answer session. If at any time during this call you require immediate assistance, please press star zero for the operator.
Speaker Change: This call is being recorded on Wednesday, May 7, 2025. I would now like to turn the conference over to Brad Joseph, VP Global Investor Relations. Please go ahead.
unknown: Good morning and good afternoon, everyone. Welcome to Perrigo's first quarter, 2025,
Speaker Change: I hope you all had a chance to review our press release issue today. A copy of the release and presentation for today's discussion are available within the investor section of the Perrigo.com website.
Speaker Change: Joining today's Fall, our President and CEO , Patrick Lockwood-Cellar, and CEO , Eduardo Bezerra.
Speaker Change: I would like to remind everyone that during this presentation participants will make certain forward looking statements. Please refer to the slides for information regarding these statements which are subject to important risks and uncertainties.
Speaker Change: We will reference adjusted financial measures that are non-GAAP in nature.
Speaker Change: JD Appendix to the earnings presentation for additional details and recommendations of all gap-to- non-GAAP financial measures presented. Keep quick items before we start. First, unless they did, all financial results discussed and presented are on a continuing operations basis.
Speaker Change: Second, Organic Growth, Excludes, Acquisitions, Devastatures, Exited Product Line, N, or Currency Fluctuations in both considerable periods.
Speaker Change: and third, Patrick's discussion will focus solely on non-GAAP results except as otherwise noted. And with that, I'm pleased to turn the call now over to Patrick.
Patrick: Thank you, Brad. Good morning, good afternoon, everyone, and thank you for joining today's call.
Patrick: I'd like to begin with an update on my progress against a 3S plan to stabilize, streamline and strengthen Perrigo.
Patrick: For the past 12 months, efforts to stabilize key parts of our business have yielded positive result.
Patrick: In our America's business, store brand OTC, we've already secured new business awards, and now largely assessing the previously disclosed losses that began impacting our top line in the second part of 2024.
Patrick: We remain on track for the new awards more than offset losses by the second quarter of this year.
Patrick: Additionally, consistent production of high quality, reliable and formular, is there to concede recovery in store ground share?
Patrick: Notably, first quarter of 2025 and four minute net sales, increased by 19% compared to the same quarter last year.
Patrick: More on both of these topics when I discuss Q1 results in a few minutes.
service to streamline our operations of unit-significant benefit.
Patrick: In the first quarter, these initiative initiatives continue to produce very positive results.
Patrick: The supply chain re-eventure program delivered an additional $8 million benefits.
Patrick: from Project Energize, achieved an additional $20 million in annual savings.
bringing the program's total annual rub rate to $159 million.
The high end of our previously disclosed range for energize.
Patrick: Actions taken to improve service levels are also paying dividends. Global service levels now at 94%.
We also remain excited about strengthening our foundation for growth.
Patrick: I'm pleased to share that the synergistic relationship between our store ground business and OTC brands is yielding positive results.
Patrick: Our short-range generates substantial cash flow, enabling us to invest further into our OTC rent.
Patrick: The strategy is already paying off and evidence by first quarter results.
Patrick: Excluding the prior year's benefit from Oakville Retail of Stocking, ROTC brands achieved solid organic growth for 5.9% year over year.
Patrick: This impressive performance was driven by strong cells of LL1, nasonets, equipment and complete.
These results reinforce our business model and our strategy.
Patrick: Lastly, to create a more efficient and effective new product pipeline, we have recently enhanced our stage game process for new product development.
And we remain excited about our high growth breaks.
Patrick: which we are expecting to begin delivering significant benefit in the second half of next year.
Patrick: At the same time, we're navigating through an uncertain macroeconomic landscape.
Patrick: So on the sewers across the self-care categories we play in, recently turned negative compared to the prior year, and compared to their long-term growth rates of 3% and more, the contraction across most categories.
Patrick: This stems from more cautious consumer behavior due in part to inflation, tariffs, interest rates, and overall reduced consumer confidence.
Patrick: Although we believe that we are well positioned in the broader environment to account for these macroeconomic uncertainties, we feel it is prudent to widen our 2025 net sales projections.
Patrick: However, with the opportunities afforded by a unique business model and clear actions to offset tariff-related cost increases, we are reaffirming our adjusted EPS range and net leverage targets.
Patrick: Furthermore, we are reaffirming on mid-term 2020-27 targets provided recently at our
Stepping back.
Patrick: Perrigo is the largest U.S. manufacturer of OTC self-care solutions by volume.
Patrick: We operate 11 manufacturing facilities across the US, enabling 85% of our OTC-finished goods to be produced lengthy by sourcing the majority of materials from codeness domestically.
Patrick: Most importantly, all this work is performed by a highly agile and productive team of 5,000 plus dedicated US employees.
Patrick: We will continue to look for opportunities to drive value from this large domestic asset base.
Patrick: Even though most of the products we sell in the US are sourced domestically, given the global nature of consumer health supply chains, there are certain inputs for our business that are exposed to tariffs.
Patrick: As you know, the tariff landscape has been extremely fluid and our team has spent considerable time building mitigation plans for multiple scenarios.
Patrick: Based on what we know today, in 2025, we expect roughly 1% grows increase to our global cost of good salt.
Patrick: On a full year basis, this rises to approximately 5.5% of global cons, all impacting our America's segment.
Patrick: Approximately 80% of the expected increase will impact our U.S. oral care category as many of its inverteous and co-resourced in China.
Patrick: The remaining 20% is expected to increase cost in our US OTC business.
Patrick: The prior top offset these cost increases through strategic price actions, in sourcing more manufacturing to our U.S. facilities where possible, and other actions, including identify new survivors.
Patrick: We're committed to protecting our P&L and also our balance sheet in this dynamic environment, which Eduardo will provide further details off.
The uncertain macroeconomic environment also presents several opportunities to Perrigo.
Patrick: A unique business model with 1100 plus molecules, across 100% price point coverage.
Patrick: coupled with our significant U.S.-based manufacturing provides us an advantage to deliver our essential self-care solutions to more customers and consumers.
Patrick: Firstly, consumer confidence in the US is at a 12 year low, and in Europe it's at the lowest level in 18 months.
Patrick: These weakening consumer expectations present significant opportunities for share games for our mid-term and store brands due to their value advantage in the marketplace.
for example
Patrick: Total US OTC storeground volume gained 50 basis points over the last four weeks as consumers are quickly adjusting their buying patterns.
Patrick: We will continue to closely monitor changes in consumer behavior and leverage demand generation
Patrick: And secondly, with our vast U.S. manufacturing footprint across OTC, infant form and oral care, we have ample opportunity to win additional new volume through contract manufacturing efforts.
Now turning to our first course at Financial Highlights.
Patrick: Organic net sales declined 0.4%, which included high-end net sales in the nutrition category, driven by the recovery in the form of an addition to the upper respiratory category.
Patrick: Offset by the impact of previously disclosed lost distribution of low margin products in US
Patrick: which is not expected to be a sales headwind going forward.
Patrick: and the prior year Oakville retail stocking of approximately $15 million dollars.
Patrick: Importantly, excluding the Lost Distribution and prior year Opil 7, Organic Net Cells grew 1.8% the prior year period.
Bruce Margin, expanded 440 basis points year over year to 41%.
Driven by business, recovering from folder .
Patrick: Operating margin for the quarter, meeting for the expanded by 550 basis points.
Patrick: driven by Grace Margin flow-through and benefits from project energides. First quarter EPS, crew by robust 107% year-over-year to 60 cents per share.
Patrick: Deen a bit further into organic net cells, both bronze and skull braille offering them upper respiratory category before well, despite the impact of known loss distribution in U.S. Stoke Brown Business.
Patrick: This category benefited from higher incidences of co-cold in the US compared to the prior year and pre-supply of the Fidium Air Brand in Europe .
Patrick: Pain and sleep pain was also impacted by known loss of US distribution, partially offset by higher incidents of co-colding US and improved supply of the self-redeemed brand in Europe .
Patrick: By Joseph Help was impacted by lower category consumption, but proton pump inhibitors used mainly for harbor, which more than offset U.S. store grown share gaps.
Patrick: and an expected decline in VMS, where we de-prioritize several SKUs in Europe .
Patrick: Lastly, as I just mentioned, our OTC brands grew solidly year over year.
Patrick: One year ago, we met a strategic pivot in U.S. store brand, which was highlighted at our February
Patrick: The pivot focused on improving forecast accuracy and customer service levels. In addition to getting from store-owned competitors, primarily through new business awards.
Patrick: I'm pleased to report that we're making significant progress with these efforts. Our service levels have improved, as I mentioned earlier, and new business awards remain on track for a positive contribution this year.
Patrick: Over the last three quarters, net business awards and losses have been a hit when to top-line growth as we executed the tibba.
Patrick: We expect this trench reverse, imported to this year, has already secured new business wins ramp up, expecting to improve America's net sales growth in the second half of the year.
Turning now to Informer.
A quality production matrix across the network that dramatically improved.
and key customer SKUs at Shell have been fully restored.
Patrick: These factors are made with first quarter infant formula next sales growth plus 19% year-of-year.
Speaker Change: In the form of industry dynamics continue to evolve, however, due to flat to defining U.S. birth rates.
Currently available manufacturing capacity and foreign manufacturing is getting <expletive> .
Speaker Change: These factors have caused many domestic brands to recently increase marketing and promotions as they compete for volume share.
Speaker Change: The short-term pricing actions of temporality reduce the price gap between national brands and store brands, slowing the pace of our store brand share recovery.
Speaker Change: We believe maintaining appropriate price gaps in this business is essential to store brand value proposition with consumers and customers.
Speaker Change: So, with this backdrop, we're engaging customers to close this short-term price gap.
Speaker Change: Additionally, spring shelf resets across several retail customers are expected to imparts our shelf placement and the number of stool-brand formula facings.
Speaker Change: At the same time, we're also reintroducing nearly 60 National Brand Equivalent SKUs in the second half of this year.
Speaker Change: We believe these actions will continue to accelerate store brand share games in 2025.
However, we are tempering our expectations of the year.
Speaker Change: Inclusion, we are steadfast on advancing our 3S Plan to stabilize streamlined and strengthened Perrigo to provide the best self-care to everyone.
Speaker Change: We delivered strong first quarter results, led by recovery in the informal business and solid organic growth in our global OTC brands.
Speaker Change: While we are operating in a uncertain macroing environment, we consume a customary industry and geopolitical risks.
taking appropriate measures to mitigate these factors.
Speaker Change: Courageingly, we believe Perrigo's unique business model provides opportunities for growth in this uncertain environment and we continue to advance our vision to provide the best self-care for everyone.
Speaker Change: Let me now turn the call over to Perrigo CFO that Eduardo Bezerra.
At what?
Eduardo Bezerra: Thank you, Patrick. Hello, everyone. Looking at the first quarter of financials, start to wait the gap to no gap summer.
Primary adjustments to our non-gab financial results were first.
Amortization Expans of $56 million and $1 million.
Eduardo Bezerra: 2. Restructuring charge of $29 billion, primarily related to the Nutrition Network of Tunization. We announced during our investor day and project energides, and 3. An usual litigation of $9 billion.
Eduardo Bezerra: All the details can be found in the non-gear reconciliation tables attached to today's press
Eduardo Bezerra: From this point forward, all financial results discussed will be on an adjusted basis unless otherwise not.
Moving to our first quarter's gross profit results.
Eduardo Bezerra: Gross Profit of $428 million, grew 8.1% or 13.8% organically, compared to the prior year, driven by business recovery in infant formula in addition to benefits from our supply chain
Eduardo Bezerra: driven by gross profits flow through and product energized cost savings which more than funded higher
Eduardo Bezerra: He is operating in control in addition to lower interest expense.
Led to a hundred and seven percent increase in adjusted earnings per share.
Eduardo Bezerra: which included unfavorable impacts of three cents from a higher tax rate and four cents from by vested businesses, accepted product lines and currency translation.
Eduardo Bezerra: Russ Margin, Expanded for 140 basis points including a 50 basis points headwind from divested businesses and accepted product lines while operating margin expanded 550 basis points including a 30 basis points headwind from these same factors.
Eduardo Bezerra: As expected, sequential growth margin expansion outpaced operating margin expansion as we invested in Ethan formula and OTC brands to drive top line growth for the year.
Eduardo Bezerra: UK and net sales performance by segment starting with CSI, reporting that sales were impacted by prior year by vestures, accepted product lines and current situation.
Eduardo Bezerra: Organic nut sales growth in the quarter remains strong at 4.5%.
Eduardo Bezerra: driven by supply recover of key products, favorable saline, and slightly higher incidence of coughing cold in certain countries, and strong sales of nicotine in the health-like styles category.
Eduardo Bezerra: In CSA, that sales declined 3.6% driven by impact of loss distribution in store brand and the prior year benefits from all peer retainers stock. The rest of the business was flat year over year. [inaudible]
Eduardo Bezerra: First quarter, operating income in both segments delivered double digit organic growth versus priority.
Eduardo Bezerra: NCSI, Operating Income of $86 million grew 10% organically, as growth profits flow through and benefits from chronic inner gifes, partially upset by divested businesses, accepted product lines and the impact of current situation.
Eduardo Bezerra: CSA operating income of $100 million grew 90% driven by infant formula business recovery and benefits from a creative initiative.
Eduardo Bezerra: These factors more than us that higher advertising promotion investments, primarily in the opio brand and even formula business.
Eduardo Bezerra: Plus, Eduardo Ernest Brasciaro, 60 cents, increased 31 cents or 177% versus prior year driven by business performance, primarily infant formula recovery and a creative initiative.
Eduardo Bezerra: A higher effective tax rate this year was upset by lower interest expenses as well.
Eduardo Bezerra: Cash on the balance sheet at the end of the first quarter was $410 million.
Eduardo Bezerra: As a reminder, first quarter typically generates the lowest cash flow in the year.
Eduardo Bezerra: Q1 operating cash was an outflow of $65 million, a sketch generation was more than upset by one higher inventory levels of $63 million, reflecting the rebuild of different former inventories, including safety stock.
Eduardo Bezerra: Two, 43 million dollars related to a security litigation settlement and three, restructuring costs of 17 million dollars.
Eduardo Bezerra: During the quarter, we also invested $26 million in cat-toe expenditures and returned $41 million to share
Eduardo Bezerra: Looking at the balance of the year, let me provide a bit of color on actions we're taking to mitigate the impacts from tariffs and optimize capital
Eduardo Bezerra: First, in our care, we have temporarily paused ordering inputs from China.
Eduardo Bezerra: As we are in process of implementing strategic price actions, in sourcing more production to our U.S. or
Eduardo Bezerra: Second, we pause the major capital investments in our nutrition network optimization until we have more clarity on the migration volume.
Eduardo Bezerra: This decision has no impact on our ability to continue delivering our affordable infant formula to consumers and husbands.
Eduardo Bezerra: and Thirds, we identified further working capital improvements across the
Eduardo Bezerra: In total, we expect these actions to mitigate estimated cash impacts from terrorists, and we are forming our natural-ever target of 3.5 times by the end of 2025.
Eduardo Bezerra: Lastly, we remain confident in our cash growth trajectory and that leverage expectations through 2027, which will be the day of our investor day.
Turning to our outlook for 2025.
As we know, the microenvironment has become more uncertain.
Eduardo Bezerra: As such, we're taking a more proven approach to our targets by widening net sales growth expectations to between 0 and 3% for a quarter and 1.5 and 4.5% for a gunny growth.
Eduardo Bezerra: We believe these adjustments reflect the right balance of risks and opportunities in the Korinne's environment at the current level of global terrorist.
Eduardo Bezerra: These ranks now include assumptions for strategic price actions and vote show elasticities of the men, slower consumption in the categories where we play and a more tempered outlook in uniform.
Eduardo Bezerra: These ranges also now include upgraded assumptions for positive volume trends that are emerging in our OTC store and value brands as consumers shift to value-oriented offers.
A few other noteworthy items [inaudible]
Eduardo Bezerra: We expect approximately a 5.5% or between 145 to 155 million draws increased to global calls from Darius on a four-year basis, which we anticipate of setting with actions we just discussed.
Eduardo Bezerra: In 2025, the growth increase of roughly 1% or approximately between 30 to 40 million dollars will likely not impact the PNL until the fourth quarter due to the timing of terrorist implementation, inventory on hand, sales velocities and inventory purchase.
Eduardo Bezerra: We are reaffirming the rest of our 2025 outlook, including constant currency adjusted the earnings per share target of $2.90 to $3.10 per share equated to strong double digits cost.
Eduardo Bezerra: Last clip, as Ethan formula recovers the store brand share, and CSA store brand new business wins Rampup, we expect phases of earnings in 2025 align with historical trends, of approximately 40% in the first half of the year, and the remaining 60% in the second half.
Eduardo Bezerra: In summary, our first water results reflected continual execution of our pre-explanation.
Eduardo Bezerra: We have been proactive in our approach to Terry's and believe we have appropriate actions in place to set a known impact while our business model is well positioned to provide consumers and customers the self-care solutions they need that have reached that.
Let me now turn the call back to Brad. Right? Bye.
Eduardo Bezerra: Instead, Eduardo, operator, can you please open the call for questions?
Thank you.
Eduardo Bezerra: Thank you. Ladies and gentlemen, we will now begin the question and answer session.
Eduardo Bezerra: Should you have a question, please press star followed by the number one on your touch-stone phone. You will hear a prompt that your hand has been raised. Should you wish to decline from the polling process, please press star followed by the number two. If you are using a speaker phone, please leave the handset before pressing any keys.
One moment please.
Speaker Change: First question comes from Chris Schott of JP Morgan. Please get it.
Speaker Change: Hi, this is Ethan on for Christmas, thanks for taking our questions.
Speaker Change: This has started off, I appreciate all the commentary on tariffs today, but as we look to 2026 and consider the impact of tariffs, how should we think about the potential impact?
Speaker Change: to EPS with where we sit today and given the action discussed to mitigate tariff exposure. And then one more question after that. Thank you.
Thank you, Ethan, for all.
Have we laid out today?
Speaker Change: all the actions that were put in place to mitigate that between pricing actions, you know, increasing sourcing
Speaker Change: of Potential Oral Care Operations as well as looking to other.
Speaker Change: Alternative Sources. We expect that to mitigate 100% of the impact that we see, not only this year, but also as we look into 2026 as well. So, we do not anticipate any major change in our projections for battery laid out, either for 25. So, we do not anticipate.
Speaker Change: and the bottom line as well as for 26 and 27.
Speaker Change: Very helpful, thank you, and then just given the updates on instant formula today, how should we think about sales ramping as we go through the year at this point and then maybe just remind us on what unnormalized level of sales looks like?
Thank you.
Speaker Change: Yeah, so as you saw, we had a significant recovery on infant formula in the first quarter, right? So about 90%, also we are at about $105 million, so we expect that
Speaker Change: Similar trajectory in the second quarter, and then wrapping up significantly in the second half.
As we have the benefits from the introduction of new worlds.
Speaker Change: The 16-year-old SKU's on the stock brand portfolio that we really believe is what consumers are looking for, and also we're watching closely on the Nutrition Business as well, the dynamics of pricing the marketplace.
Speaker Change: and Potential Promotions of National Brands and Health and backing back that, but at East Aid, we expect.
Speaker Change: Similar sales in the first half between Q1 and Q2 that growing almost 50% in the second half of the year.
Speaker Change: I appreciate all the updates today. Thank you so much and I'll pass it on.
Speaker Change: Your next question comes from Susan Anderson of Canacor Genuity. Please go ahead.
Hi, good morning. They stop in the quarter.
Susan Anderson: Thanks for the additional details there on the infant formula. I guess maybe just one follow-up. You mentioned the potential to win some contract manufacturing. I guess I'm curious are you already seeing brands come back to you to manufacture and then do you have any updated thoughts just on the government guidelines for international manufacturing potentially getting walked back in the back half of the year? Yes, I do.
Susan Anderson: Hi Susan, this is Patrick, Hope you're well. Thank you for the question. Yeah, we are seeing an increase in activity.
Speaker Change: For contract manufacturing, obviously our competitors will be looking at a domestic supply route and we continue to negotiate through those.
Um, um,
as it relates to informers specifically.
Speaker Change: just to add to the question. We're very encouraged by the FDA Commission as both recent comments where the FDA is committed to stepping up foreign inspections on terms similar to how they run inspections on U.S. manufacturing facilities, i.e. no free notification.
Speaker Change: We continue to work with the FDA as we consider formulation of regulatory changes. We're encouraged by the comments that the Commissioner will follow good signs and reliability.
Speaker Change: that we are fully utilizing all the capacity of world-class manufacturers available in the US, whilst adhering to the highest efficacy of safety standards in the world-class formula.
Okay, great.
Speaker Change: That's exciting. I guess maybe just a couple follow-up here. So just on the organic sales and kind of how it played out in the quarter, it looked like some areas such as Kolkhoff were a bit better than expected and then it sounded like there was some a little bit lighter sales and the digestive health category. I guess maybe if you could talk a little bit about kind of what to row that and then also where there are other areas that kind of played out a little bit different than you expected in the quarter. Here.
Yeah, I'll add a comment, and then, and then Eduardo, I'm...
Bye.
Eduardo Bezerra: There were no major surprises. The digestive wellness reflects distribution effects as we exit into certain businesses last year and that just flowing through into fairly predictable sort of sales patterns in the quarter. Yes, indeed, in the America's upper respiratory was stronger.
Eduardo Bezerra: because that was actually somewhat offset by somewhat weaker incidents in Europe . So I think the less effective than two for the total company is quite balancing.
Um...
Eduardo Bezerra: We, and I'm going to talk more about this later on. We often don't focus in these discussions on the international business.
Eduardo Bezerra: and actually the international business and a double digit from the growth quarter approximately five percent, sales growth quarter which is extremely encouraging and we are performing better than some cheap competitors.
Eduardo Bezerra: So almost 6% global OTC brand growth, but in Europe , very, very strong share growth on our key focus brands that I talked about in the investor day.
So, the report...
Eduardo Bezerra: NetNet, the organic sales were broadly in line with our expectation in terms of contribution and we expect to see particularly in corner two as we see recovery in the US stole brand business, acceleration of America's revenue as well. So for us, largely on track
Eduardo Bezerra: and very encouraging OTC brand performance as well, which member operates at approximately 50% to 60% higher growth margin than the balance of the business. So growth on that is disproportionately positive.
Speaker Change: Yeah, and Susan just to add a little bit color, so...
Uh...
Speaker Change: It's definitely on CSCA, right? So remember, we have been flagging things last year that we would see a transition year, where we would see benefits of the contracts that were winning versus losses to start.
Speaker Change: Flipping in the second quarter and I have a significant benefit in the second half of the year. So Q1 is still reflected some of that.
Speaker Change: And so if you exclude the impact of that lost distribution and remember, Q1 last year, we did the first positioning of product on O'Pill with many retailers, so if you exclude that...
Speaker Change: that one time the fact, you know, our organic net sales rule, almost 2% so...
Breaking line with Watu, we were originally expecting so...
Speaker Change: Specifically, on what you said by gestate health, we saw a little bit shift on consumption between DPI versus embedded, you know, and that's just something that happened through the sub-contaborate percent, but nothing significantly concerning for the rest of the year.
Okay, perfect.
Speaker Change: I think that sounds great and the international sounds really strong. Really quick, Eduardo, if I could just ask on the growth margin, I know that was greater than expected in the first quarter, a lot of that driven by the infant formula business. I think you guys had said, you know, for around 40% for the year previously, so I guess should we expect it to be a little bit better now because of the infant formula or how do we think about the growth margin, the rest of the year? Thanks.
Speaker Change: We're still expecting 40% for the four years, Susan, a couple of things there, right? So...
Speaker Change: In Q1, we had the better performance of our manufacturing operations than we originally anticipated, which is very positive so and that's connected with what Patrick mentioned, and operating a much more reliable sense that provides...
Signed it's got benefits in terms of...
Speaker Change: a lower impact of obsolescence, stoppage, et cetera. So that turns into a much more efficient operations there. So that was one of the key drivers for that. [inaudible]
Speaker Change: And that's what we're watching closely, you know, with a not expect to see the same level of high efficiency, but we're tracking that close.
Speaker Change: Okay, great. Thank you so much. Good luck the rest of the year.
Thank you.
Speaker Change: Your next question comes from Keith Devas of Teferis. Please go ahead.
Keith Divas: Hey, good morning. Thanks for the question. I'd love to dig in a little bit more into...
Keith Divas: The whitening range for the net sales for the year. I guess in one hand you call it out to consume more uncertainty, which is fair. But you're also talking about how that may lead to store brand share gains, some of the distribution wins, as well as, you know, lower expectations for infant formula, just given what some of your competitors are doing. Thanks, Joe.
It'd be great if you could, I guess.
Keith Divas: highlight some of the puts and takes on what's really driving or the biggest driver of, you know, widening that range for the year. Just given, you know, I guess you called out some.
Keith Divas: some wins and things that should be tailwinds for you guys and so I'm very curious if you could just unpack it a little bit. Thank you.
Keith Divas: Hi, Keith, this is Patrick Trustywell, thanks for joining this morning. A very fair question and I think implicit in some of the language that you've used is exactly what we face, which is dynamic, real-time shifts.
Keith Divas: We are working on a large number and an increasing number of opportunities in the US.
Keith Divas: on Preventive Takeaway, we're working with retailers on implications of consumers trading down and what that means and the distribution.
Shelf, Promotional Work, 17th
The key concern, obviously, with the...
Keith Divas: Erosion of Consumer Confidence is maintaining household penetration in consumer goods catchphrase.
Keith Divas: We're well positioned to do that. We operate across all price tiers and can offer a superior value as consumers are evaluating their discretionary income choices.
Keith Divas: So that is active, current word, but it's absolutely not a full-class great yet, it's current word.
Um...
Keith Divas: Why, therefore, soften just as we work through implications of discretionary income impacts.
Keith Divas: What does that mean? Whilst we have a broad range of hypotheses, these need to be converted into...
Keith Divas: plans and forecasts, and we're just not at the stage of doing that. So frankly, for somebody who was prudent to just widen the range, but provide commentary that we're managing risk.
Keith Divas: and aggressively pursuing opportunity as well. I'm from former in particular. The store brand share recovery has been very good. It's been impacted in the very short term.
Keith Divas: Frankly by some surprising promotional activity in water is an extremely inelastic category. These don't tend to lead to long-term share gains, they tend to be value-erosive.
Keith Divas: But we have to respond to that in order to maintain the game on school ground. That's very important to consumers, obviously very important to Perrigo.
Keith Divas: and we're committed to do that and we'll support Stool Brand accordingly and are holding our end-to-year exit share target. That's just extremely important structurally to the health of this business for us in the midst of.
Keith Divas: So, sorry, the range reflects the broad range of work and the dynamic nature of the situation and the fact that you have consumer patterns and flux at the moment.
No, I think that's bottom.
Keith Divas: Great, that's very helpful. And maybe just a quick follow up as the margin has come back on the gross margin side. You guys are, you know, slowly choosing to to reinvest with SGNA up.
Keith Divas: It would be great if you could add some context on where specifically you're choosing to reinvest in what parts of the business I guess you're prioritizing first, and I'll pass it on. Thank you.
Keith Divas: Yeah, so, Keith, as we talked about a bit so, if a formula is a Q1, so as we talked about, we're working with all the retailers.
Keith Divas: We're heading back about 60 new SKUs, so we want to make sure that...
Keith Divas: You know, consumers see that on shelves and understand that they have option at the time, a critical time right now that, you know, consumer confidence and economics are being stretched, you know, having more store brands.
Keith Divas: The number of FT used to choose is critical, so making sure that…
Keith Divas: We have that full visibility at the consumer level, it's one second, Opiro as well.
Keith Divas: Remember, this is the second year that, you know, we launched this new brand and we continue to see significant progress there. So we expect consumption.
Keith Divas: This year to more than to almost double what we saw last year, and so we want to make sure that we continue with the right trajectory.
Thanks, we take the next question please.
Speaker Change: The next question comes from Korinne Wolfmeyer of Piper Sandler. Please go ahead.
Speaker Change: Hi, good morning. This is Sarah on For Cream. Thanks for taking our questions. First, I talked about taking some pricing, any color around when that will come in, which products it would be on and then how that compares to past price actions. Thank you very much.
So, you say specifically on the rockier business, Korinne?
Yeah.
Yeah, so, I'm...
Speaker Change: So we're working right now with all the major retailers on that, right? So first of all it's really explaining
the impact of terrorists across the airport volume.
Speaker Change: and what are the actions that we could do jointly between looking to alternative sources. So we have a manufacturing facility in Michigan for oral care that has available capacity.
Speaker Change: That's a key opportunity that will work with the retailers to see how much can we bring in houses versus China.
Speaker Change: But there will be an adjustment on Bryan, Ethan, by doing that. So we're working with Daniel Bezerra and we expect some of those actions to take place in the next three months that we're going to start seeing that in the marketplace.
Speaker Change: Okay, thanks. Very helpful. And then it just fell on the brand divestors and exits that you laid out at the investor day. Any color around what kind of progress has been made so far and then how much we can expect for the remainder of the year. And then if there are any impact from the current market conditions that have altered plans here. Thank you.
Speaker Change: Well, so specifically to post two categories that we're assessing, we continue to do the work there, of course, you know, specifically on the US market, there's been a little bit pause.
Speaker Change: on looking to some of those investments, but we're watching that closely and we are continuing to assess any further opportunity there. On the brand side, we continue to look into opportunities, maybe on our international portfolio, nothing significant to share at this stage.
Thank you, Sarah. We are the next question, please.
Speaker Change: Your next question comes from Daniel Biolsi of Hedge Eye. Please go ahead.
Daniel Baiozzi: Patrick and Eduardo, I really appreciate all the details around Terrace. I'm wondering, should we anticipate any lower sales from the upper respiratory products in the fall because of the late cold season order that we had?
Speaker Change: Hi, thank you for the question of joining us this morning.
I've not seen any data that suggests that.
Speaker Change: We were checking yesterday. I've not seen any imagery destoffing impacts for us.
Speaker Change: Office is way too early to predict incidents at this stage. We tend to just work from a...
A normal season-based assumption, and then provide...
Speaker Change: Guidelines in terms of should it be stronger as that flow through to production and then should it be weaker than normal implications of course for production, spend etc. It's just really about real-time cash flow management for having the agility to respond downside and upside. [inaudible]
In terms of... [inaudible]
Speaker Change: Are we seeing material impact from tariffs and upper respiratory? No, as we talked about earlier, 85 to 90% of our production of US sold product is in the US.
Speaker Change: We have available capacity. Should there be a strengthening in the season? And should we other...
Speaker Change: Brands, Manufacturers, looked to utilize our domestic capacity to minimize the impact of tariffs to them. We continue to pursue both of those, but now, not anticipating any significant impact. [inaudible]
Speaker Change: Thank you. Can I do a follow-up on the nutrition category in terms of the inventory rebuild across all customers, not just your largest chains?
Speaker Change: I just want where you're on shelf availability is and then the Instaq for the smaller excuse.
Speaker Change: Yeah, very good, good question. We are rebuilding that rapidly. I probably characterize it as we are at going levels of on-shelf availability. Probably the second big distribution surge that you're going to see across the rest of this year is we're introducing 60 skews.
Speaker Change: Those shelf resets will be happening any day now, through the next couple of months. That will also increase our share of distribution, that will be a positive impact on still ground share trajectory.
Speaker Change: So on track I'm strengthening fundamentals of the infant nutrition go to market over the next few weeks.
Thank you.
Thanks, Daniel.
Speaker Change: The last question comes from Chris Schott of JP Morton. Please go ahead.
Speaker Change: Hi, this is Ethan on for Chris. Just one more follow-up question from us. As you think about the potential impact of Pharma-specific tariffs,
Speaker Change: To what extent could that have an impact on the business? And then maybe any commentary on how quickly you could offset that impact as well. Thank you so much.
Speaker Change: Hi Chris, good to hear from you. I'll start and then Eduardo gives a more detail on.
Speaker Change: This has been firmly in the fluid for us trying to understand tariffs as it has for multiple industries.
Speaker Change: We continue to see evolution in what tariffs, what level of tariffs, what specific country impacts, etc.
Thank you.
Faced upon on
Speaker Change: Our current assumptions, we could see up to about 100 million impact, how we will mitigate that is through pricing.
It's true, onshoreing, is looking at alternative supply routes.
including where we saw ZPI.
Speaker Change: and it is that latter that is probably quite meaningful for us. So basically, whatever we've done on all the care is what we would look to execute across farmer.
Speaker Change: 45% of our businesses in Europe as you know and that's not impacted . . .
Speaker Change: So this is US, we have a playbook now and that's what we're going to execute here. We're in closely as on with the administration providing input.
Speaker Change: to have a thinking about farmer and the implications for farmer industry, given the administration's stated aim of reducing cost burden to the patients and consumers. This needs to be thought through extremely carefully.
Speaker Change: We've had to playbook ready, we're just awaiting what these decisions and impacts are.
Speaker Change: It seems to be a case of whatever is announced.
who potentially then changes its further excuse.
Eduardo, no nothing else, go ahead and switch. [inaudible]
Speaker Change: Thank you, ladies and gentlemen. That concludes our question and answer session. I will now turn the conference back over to Patrick Lockwood Taylor, CEO .
Speaker Change: Thank you very much, and thank you to everyone for joining today. As you heard today, we're making great progress in our stabiliser initiatives.
Speaker Change: really benefiting our America's business. We're also maintaining our EPS guidance whilst broadening the range on revenue which we feel is prudent enough.
Speaker Change: But you heard me mention earlier, we often don't spend enough time on the contribution and the importance and the growth of our international business which has really turbocharged growth over the past few years and now accounts for well over 40% of our global sales and that's accelerating.
Speaker Change: In quarter one, net sales and the international business were a mid-single digit plus 5% and Organic Adjusted Hawaii Group plus 10%.
Speaker Change: Just to compare some purposes, the justice ROI of the international business was over 85 million in quarter one million as much as the America's business so over 100 million and that gap is now that's very important
Speaker Change: The prospective business is now almost four and a half times larger in terms of revenue than our entire informal business, and they're approaching the same sizes as our USOTC business. It is a large and accelerating ponds of the Perrigo enterprise.
Speaker Change: This business and why it's important to really understand it also embodies the potential of about 3S plan on a global basis.
Driving benefits from street 9-E [inaudible]
Speaker Change: As we consolidate brains, as we consolidate categories, as we consolidate the organizational structure and the supply strategy.
Speaker Change: He's also benefited enormously from strength and the initiatives. We're seeing disproportionate share growth in our highest potential brands that we talked about that are of every investor day.
Speaker Change: We are, as you heard, disproportionate driving investment and focus on those most inclusive categories of brands and geographical operations.
Speaker Change: As you have me talk to, we're moving to regional clusters passing those savings to bottom line.
Speaker Change: So, in closing, we're advancing our 3S Plata Stabilized Streamline and Strengths in Parago, and we have clearer initiatives being
with a hundred plus molecules and additional 150 exits.
Of course, 100% of price playing coverage.
Speaker Change: Perrigo's unique business model provides significant opportunities for growth, especially in some certain environment. As we convert those opportunities, you will hear those being reflected in our learnings, announcements and our future work.
Thank you very much for joining us.
Speaker Change: This concludes today's conference. Thank you for attending. You may now disconnect your lines.